Literature DB >> 33479394

PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.

Hiroshi Nakano1, Motonobu Saito2, Shotaro Nakajima1,3, Katsuharu Saito1, Yuko Nakayama4, Koji Kase1, Leo Yamada1, Yasuyuki Kanke1, Hiroyuki Hanayama1, Hisashi Onozawa1, Hirokazu Okayama1, Shotaro Fujita1, Wataru Sakamoto1, Zenichiro Saze1, Tomoyuki Momma1, Kosaku Mimura1,5, Shinji Ohki1, Akiteru Goto6, Koji Kono1.   

Abstract

Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected GC samples and publicly available microarray data and The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV (+) GC. We found that high levels of PD-L1 overexpression in EBV (+) GC were caused by focal amplification of CD274. By contrast, relatively high expression of PD-L1 in tumor tissue and infiltrating immune cells correlated with CD8 lymphocyte infiltration and IFN-γ expression via IRF3 activation. Since we reported previously that PD-L1 expression is associated both with the presence of CD8 T cells in the tumor microenvironment and with IFN-γ expression in GC, we examined a database to see whether IFN-γ-associated overexpression of PD-L1 plays a significant role in EBV (+) GC. Immunohistochemical staining showed that expression of the IRF3 signature in clinical GC samples was higher in EBV (+) than in EBV (-) cases. The data presented herein reveal a unique dual mechanism underlying PD-L1 overexpression in EBV (+) GC: high focal amplification of CD274 or IFN-γ-mediated signaling via activation of IRF3.

Entities:  

Year:  2021        PMID: 33479394     DOI: 10.1038/s41598-021-81667-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  30 in total

1.  Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.

Authors:  Yuko Nakayama; Kosaku Mimura; Ley-Fang Kua; Hirokazu Okayama; Aung Kyi Thar Min; Katsuharu Saito; Hiroyuki Hanayama; Yohei Watanabe; Motonobu Saito; Tomoyuki Momma; Zenichiro Saze; Shinji Ohki; Yoshiyuki Suzuki; Daisuke Ichikawa; Wei-Peng Yong; Koji Kono
Journal:  Gastric Cancer       Date:  2020-05-04       Impact factor: 7.370

Review 2.  Update on Epstein-Barr virus and gastric cancer (review).

Authors:  Aya Shinozaki-Ushiku; Akiko Kunita; Masashi Fukayama
Journal:  Int J Oncol       Date:  2015-01-28       Impact factor: 5.650

3.  Epstein-Barr virus infection as an epigenetic driver of tumorigenesis.

Authors:  Atsushi Kaneda; Keisuke Matsusaka; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Cancer Res       Date:  2012-07-03       Impact factor: 12.701

4.  Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes.

Authors:  Keisuke Matsusaka; Atsushi Kaneda; Genta Nagae; Tetsuo Ushiku; Yasuko Kikuchi; Rumi Hino; Hiroshi Uozaki; Yasuyuki Seto; Kenzo Takada; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Cancer Res       Date:  2011-10-11       Impact factor: 12.701

5.  Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.

Authors:  Julie George; Motonobu Saito; Koji Tsuta; Reika Iwakawa; Kouya Shiraishi; Andreas H Scheel; Shinsuke Uchida; Shun-Ichi Watanabe; Ryo Nishikawa; Masayuki Noguchi; Martin Peifer; Se Jin Jang; Iver Petersen; Reinhard Büttner; Curtis C Harris; Jun Yokota; Roman K Thomas; Takashi Kohno
Journal:  Clin Cancer Res       Date:  2016-09-12       Impact factor: 12.531

6.  ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.

Authors:  Koji Kase; Motonobu Saito; Shotaro Nakajima; Daisuke Takayanagi; Katsuharu Saito; Leo Yamada; Mai Ashizawa; Hiroshi Nakano; Hiroyuki Hanayama; Hisashi Onozawa; Hirokazu Okayama; Hisahito Endo; Shotaro Fujita; Wataru Sakamoto; Zenichiro Saze; Tomoyuki Momma; Kosaku Mimura; Shinji Ohki; Kouya Shiraishi; Takashi Kohno; Koji Kono
Journal:  Carcinogenesis       Date:  2021-02-11       Impact factor: 4.944

7.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

8.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

9.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

10.  PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.

Authors:  Kousaku Mimura; Jun Liang Teh; Hirokazu Okayama; Kensuke Shiraishi; Ley-Fang Kua; Vivien Koh; Duane T Smoot; Hassan Ashktorab; Takahiro Oike; Yoshiyuki Suzuki; Zul Fazreen; Bernadette R Asuncion; Asim Shabbir; Wei-Peng Yong; Jimmy So; Richie Soong; Koji Kono
Journal:  Cancer Sci       Date:  2017-11-18       Impact factor: 6.716

View more
  7 in total

1.  Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.

Authors:  Wei-Tong Zhang; Gui-Lu Zhu; Wu-Qin Xu; Wei Zhang; Hui-Zhen Wang; Ya-Bing Wang; Yong-Xiang Li
Journal:  Diagn Pathol       Date:  2022-07-16       Impact factor: 3.196

2.  Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.

Authors:  Tsutomu Yoshida; Go Ogura; Mikiko Tanabe; Takuo Hayashi; Chiho Ohbayashi; Mizutomo Azuma; Chikara Kunisaki; Yoichi Akazawa; Soji Ozawa; Sohei Matsumoto; Takayoshi Suzuki; Akira Mitoro; Tetsu Fukunaga; Akiko Shimizu; Go Fujimoto; Takashi Yao
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.742

Review 3.  Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.

Authors:  Glauco Akelinghton Freire Vitiello; Wallax Augusto Silva Ferreira; Vladmir Cláudio Cordeiro de Lima; Tiago da Silva Medina
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

4.  Novel approach to identify putative Epstein-Barr-virus microRNAs regulating host cell genes with relevance in tumor biology and immunology.

Authors:  Simon Jasinski-Bergner; Juliane Blümke; Marcus Bauer; Saskia Luise Skiebe; Ofer Mandelboim; Claudia Wickenhauser; Barbara Seliger
Journal:  Oncoimmunology       Date:  2022-05-01       Impact factor: 7.723

5.  The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer.

Authors:  Yuan Cai; Rong Zeng; Jinwu Peng; Wei Liu; Qingchun He; Zhijie Xu; Ning Bai
Journal:  Aging (Albany NY)       Date:  2022-09-12       Impact factor: 5.955

Review 6.  Landscape of EBV-positive gastric cancer.

Authors:  Motonobu Saito; Koji Kono
Journal:  Gastric Cancer       Date:  2021-07-22       Impact factor: 7.370

7.  Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma.

Authors:  Xiaoyu Li; Xingchen Peng; Sha Zhao; Hong Zhang; Yong Jiang; Fei Liu; Ping Ai
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.